U.S. markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.94 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.92 (-0.21%)
     
  • Crude Oil

    83.98
    +1.48 (+1.79%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • Silver

    24.39
    +0.22 (+0.91%)
     
  • EUR/USD

    1.1650
    +0.0019 (+0.16%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • GBP/USD

    1.3760
    -0.0036 (-0.26%)
     
  • USD/JPY

    113.4800
    -0.5080 (-0.45%)
     
  • BTC-USD

    61,461.95
    -1,680.28 (-2.66%)
     
  • CMC Crypto 200

    1,453.34
    -49.69 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.27 (+0.34%)
     

Novavax (NVAX) Begins Clinical Study on COVID/Flu Combo Jab

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Novavax NVAX announced that patient enrollment has begun in phase I/II study to evaluate a combination of its COVID-19 vaccine candidate NVX-CoV2373 and seasonal influenza vaccine candidate, NanoFlu.

The phase I/II study will evaluate the safety and immunogenicity of both NVX-CoV2373 and NanoFlu in a single formulation along with Novavax's patented saponin-based Matrix-M adjuvant to boost immune response.

While separately both the vaccines have already demonstrated encouraging results in phase III clinical studies, Novavax announced positive data from a preclinical study evaluating the combination vaccine in May 2021. Data from the preclinical study demonstrated that the combined COVID-19 and seasonal influenza vaccines achieved positive immune responses against both the indications.

Shares of Novavax have rallied 139.3% so far this year in comparison with the industry’s 1.2% growth.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Novavax’s NVX-CoV2373 and NanoFly are both currently in late-stage development. In June, the company announced data from the phase III PREVENT-19 study, which evaluated NVX-CoV2373 in the United States and Mexico. The study met its primary endpoint by demonstrating an overall vaccine efficacy of 90.4%. The vaccine also provided 100% protection against moderate and severe disease - a key secondary endpoint.

The company also announced positive top-line data from a pivotal phase III study, which demonstrated both the efficacy and safety of NanoFlu in March 2020. The study met all the primary goals and achieved statistical significance in key secondary endpoints.

We remind investors that Novavax has not filed regulatory applications with the FDA for either of the vaccines. The company plans to apply to the FDA for emergency use authorization for NVX-CoV2373 in fourth-quarter 2021.

If approved, NVX-CoV2373 will face stiff competition from COVID vaccines developed by AstraZeneca AZN, Moderna MRNA and Pfizer PFE/BioNTech, which are already in the market. Pfizer’s COVID vaccine became the first to receive full approval in the United States in August 2021. Meanwhile, Moderna has also filed regulatory applications seeking full approval for its COVID vaccine in the United States.

Novavax, Inc. Price

Novavax, Inc. Price
Novavax, Inc. Price

Novavax, Inc. price | Novavax, Inc. Quote

Zacks Rank

Novavax currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN) : Free Stock Analysis Report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Moderna, Inc. (MRNA) : Free Stock Analysis Report

Novavax, Inc. (NVAX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research